EINDHOVEN, NL, Sept. 7, 2023 /PRNewswire/ — Sirius Medical, a leader in value-based healthcare and surgical marker navigation announced that LifeBridge Health, with locations across Maryland, will offer tumor localization with the Pintuition® surgical marker navigation system.
With many breast cancers being diagnosed at an early stage, the tumor often cannot be seen during surgery. Pintuition is a next generation technology that is rapidly changing how tumors are localized. The system use GPSDetect™ software providing unmatched directional guidance to locate tumors easily and accurately. Patients benefit from enhanced diagnostic accuracy, reduced procedure times, and improved treatment planning.
“We are always searching for ways to create a better experience for our patients, adding new technology with surgical marker navigation to our breast cancer program further enhances our patient-centered care,” says Dona Hobart, M.D., LifeBridge Health Medical Group.
“We are pleased to welcome LifeBridge Health to our expanding customer base in the U.S.,” states Bram Schermers, CEO, Sirius Medical. “Physicians and administrators are embracing surgical marker navigation validating its simplicity, precision, and affordability.”
For more information about Sirius Medical please visit www.sirius-medical.com
About Sirius Medical
With its roots deeply embedded in the Netherlands Cancer Institute, Sirius Medical is dedicated to improving care for cancer patients by delivery of unsurpassed, yet affordable solutions that enable precise and efficient removal of tumors. The Pintuition technology is precise, simple, affordable and both CE marked, and FDA cleared. Sirius Medical is rapidly expanding with over 14,000 procedures worldwide in over 175 centers combined with a global commercial network covering the USA, Western Europe and Australia–New Zealand.
Media Contact:
Benjamin Tchang – Corporate contact
benjamin.tchang@sirius-medical.com
+31 857 732 727 (The Netherlands)
SOURCE Sirius Medical
– Largest hypertension trial of an aldosterone synthase inhibitor to date demonstrated the efficacy of…
Oslo, 24 May 2025: Zelluna ASA (the "Company") refers to the resolution by the Company's…
Los Angeles, CA and Vancouver, BC, May 23, 2025 (GLOBE NEWSWIRE) -- BioSig Technologies, Inc.…
$3.25 million upfront with up to an additional $6.5 million of potential aggregate gross proceeds upon…
INDIANAPOLIS, May 23, 2025 /PRNewswire/ -- This Memorial Day Weekend, the spotlight won't only be on…
IRVING, Texas, May 23, 2025 /PRNewswire/ -- Caris Life Sciences® ("Caris"), a leading, patient-centric, next-generation AI…
![](data:image/svg+xml;charset=utf-8,<svg height="32px" width="32px" xmlns="http://www.w3.org/2000/svg" version="1.1"/>)
![](data:image/svg+xml;charset=utf-8,<svg height="215px" width="400px" xmlns="http://www.w3.org/2000/svg" version="1.1"/>)
![](data:image/svg+xml;charset=utf-8,<svg height="12px" width="12px" xmlns="http://www.w3.org/2000/svg" version="1.1"/>)
![](data:image/svg+xml;charset=utf-8,<svg height="400px" width="1000px" xmlns="http://www.w3.org/2000/svg" version="1.1"/>)
